5-amino-1-[(3-fluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide | 119222-38-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-amino-1-[(3-fluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide
• 英文别名: 5-amino-1-(3-fluorobenzyl)-1H-1,2,3-triazole-4-carboxamide；5-amino-1-[(3-fluorophenyl)methyl]triazole-4-carboxamide
• CAS: 119222-38-7
• 化学式: C₁₀H₁₀FN₅O
• 分子量: 235.221
• InChiKey: PPJSXEIGKDPRNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  99.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-amino-1-[(3-fluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide 在 溶剂黄146 作用下， 生成 3-(3-fluorobenzyl)-3H,6H,7H-1,2,3-triazolo[4,5-d]pyrimidin-7-one
  参考文献：
  名称：

  3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and

  摘要：

  该发明涉及3H-1,2,3-三氮唑[4,5-d]嘧啶衍生物，特别是一般式##STR1##的取代3-苄基-3H-1,2,3-三氮唑[4,5-d]-嘧啶化合物，其中Ph代表被卤素、较低烷基、三氟甲基和/或氰基取代的苯基基团，R.sub.1代表自由氨基或被脂肪基、环脂肪基、环脂肪基-脂肪基和/或酰基取代的氨基，R.sub.2代表氢、较低烷基、自由氨基或被脂肪基、环脂肪基、环脂肪基-脂肪基和/或酰基取代的氨基，以自由形式或盐形式存在，但在式I的自由形式化合物中，如果R.sub.1代表N,N-二-C.sub.1-C.sub.6-烷基氨基，其中两个N-C.sub.1-C.sub.6-烷基基团可以相同也可以不同，N-单-C.sub.1-C.sub.6-烷基氨基或氨基，R.sub.2不是氢且不是C.sub.1-C.sub.6-烷基，如果Ph代表被卤素或三氟甲基单取代的苯基基团，以及在自由形式的式I化合物中，其中Ph是o-氟苯基，R.sub.1是N-单-甲基氨基或氨基，R.sub.2是氢或甲基，或者Ph是o-氟苯基、o-氯苯基或m-三氟甲基苯基，R.sub.1是N,N-二-甲基氨基，R.sub.2是氢，或者Ph是m-氟苯基、p-氟苯基、o-氯苯基、o-三氟甲基苯基、m-三氟甲基苯基或p-三氟甲基苯基，R.sub.1是N-单-甲基氨基，R.sub.2是氢。这些化合物和盐可用作药用活性成分，并可按已知方法制备。

  公开号：

  US05204353A1

文献信息

• [EN] PHARMACOLOGICAL MODULATORS OF NAV1.1 VOLTAGE-GATED SODIUM CHANNELS ASSOCIATED WITH MECHANICAL PAIN<br/>[FR] MODULATEURS PHARMACOLOGIQUES DES CANAUX SODIQUES VOLTAGE-DÉPENDANTS NAV1.1 ASSOCIÉS À DES DOULEURS MÉCANIQUES
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2017147379A1

  公开（公告）日：2017-08-31

  The present invention provides the use of compounds which selectively block the Nav1.1 subtype of voltage-gated sodium (Nav) channels, whose role in nociception and pain has been unexplored. The present invention demonstrates that Nav1.1-expressing fibers are modality specific nociceptors: their activation elicits robust pain behaviors without neurogenic inflammation and produces profound hypersensitivity to mechanical, but not thermal, stimuli. In the gut, high-threshold mechanosensitive fibers also express Nav1.1 and show enhanced toxin sensitivity in a model of irritable bowel syndrome. The present invention provides an unexpected role for Nav1.1 in regulating the excitability of sensory nerve fibers that underlie mechanical pain, and provides methods of screening for other peptides and small molecules that can modulate Nav1.1 channels and their use in treatment of neurological disorders.

  本发明提供了选择性阻断电压门控钠（Nav）通道的Nav1.1亚型的化合物的使用，其在疼痛感知和疼痛中的作用尚未被探索。本发明证明Nav1.1表达的纤维是特定于模态的伤害感受器：它们的激活引起强烈的疼痛行为，没有神经源性炎症，并产生对机械刺激的深度过敏，而不是对热刺激的过敏。在肠道中，高阈值机械敏感纤维也表达Nav1.1，并在肠易激综合征模型中显示出增强的毒素敏感性。本发明提供了Nav1.1在调节感觉神经纤维的兴奋性方面的意外作用，这些感觉神经纤维是机械性疼痛的基础，并提供了筛选其他肽和小分子以调节Nav1.1通道及其在治疗神经系统疾病中的使用的方法。
• 3H-1,2,3-Triazolo[4,5-d]pyrimidine
  申请人：CIBA-GEIGY AG

  公开号：EP0288431B1

  公开（公告）日：1992-08-19
• RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20150368211A1

  公开（公告）日：2015-12-24

  The present invention provides compounds of formula I or a salt, solvate, or stereoisomer thereof, wherein X is H, or an electron withdrawing group such as a halogen, NH 2 , NO 2 , SO 2 , CN, or a C 1 -C 6 alkyl group; Alk is C 1 -C 3 alkyl; R 1 is H, C 1 -C 6 alkyl, which may be substituted with OH, NH 2 , acyl, sulfonyl, and cyano groups; and R 2 , is C 1 -C 6 alkyl, which may be substituted with OH, NH 2 , acyl, sulfonyl, and cyano groups. Pharmaceutical compositions comprising these compounds and/or rufinamide are also provided. Methods for prevention and treatment of epilepsy disorders such as Lennox-Gastaut Syndrome (LGS), and modulation of voltage-gated sodium (Nay) channels are Nav1.1 channels by administration of these compounds and/or rufinamide are also provided.
• DERIVATIVES OF RUFINAMIDE AND THEIR USE IN INHIBTION OF THE ACTIVATION OF HUMAN VOLTAGE-GATED SODIUM CHANNELS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20170029382A1

  公开（公告）日：2017-02-02

  The present invention provides compounds of formula I which are capable of inhibition of the activation of hNav1.1 or hNav1.6 sodium channels in neurons. Pharmaceutical compositions comprising these compounds are also provided. Methods for prevention and treatment of neurological disorders, including, for example, seizures and seizure disorders, including Lennox-Gastaut Syndrome, Dravet syndrome, epileptic encephalopathies, autism, Familial hemiplegic migraine (FHM), anxiety disorders, including Post-traumatic stress disorder (PTSD), panic disorder and obsessive-compulsive disorder, neuropathic pain, and Rett syndrome by administration of these compounds are also provided.
• US5204353A
  申请人：——

  公开号：US5204353A

  公开（公告）日：1993-04-20